2020 Year in Review - Breast Cancer
Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study
In a range of groups with PIK3CA alterations, recent findings demonstrate a clear and consistent clinical benefit of alpelisib when combined with fulvestrant, which was detected in circulating tumor DNA by next-generation sequencing.
Overall Survival Benefit with Ribociclib plus Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: 4-Year Follow-Up Study of MONALEESA-7
Updated overall survival results from the phase 3 MONALEESA-7 trial show that in a 4-year extended follow-up study of pre- and perimenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, ribociclib plus endocrine therapy exhibited a clinically relevant overall survival benefit.
BYLieve Study Results Support the Use of Alpelisib Combined with Fulvestrant for Hormone Receptor–Positive, HER2-Negative, PIK3CA Mutation–Positive Advanced Breast Cancer
BYLieve study results show that alpelisib combined with fulvestrant demonstrates clinically meaningful efficacy and manageable toxicity in patients with hormone receptor–positive, HER2-negative, PIK3CA mutation–positive advanced breast cancer.
Analysis from the PALOMA-3 clinical trial showed that the combination of palbociclib and fulvestrant improved overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer.
Favorable Tolerability Profile of Sequential Radiation Therapy in Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer
While radiation therapy is not currently used in combination with CDK4/6 inhibitors in clinical trial protocols, findings from this study support future consideration of this approach in clinical studies.
Expanded Safety Analysis of the Phase 3b CompLEEment-1 Trial with Ribociclib plus Letrozole in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In this broad study of a diverse population, adverse events associated with the combination of ribociclib plus letrozole were manageable and consistent with previous phase 3 trials of the same combination, and adverse events of special interest markedly decreased over time.
A Network Meta-Analysis of Treatment-Related Adverse Events of Various CDK4/6 Inhibitors in Metastatic Breast Cancer
While showing comparable efficacy, the 3 approved CDK4/6 inhibitors differ in safety and tolerability profiles.
Maintenance Therapy with Everolimus plus Aromatase Inhibitors in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Updated Analyses of the Phase 3 Randomized MAIN-A Trial
Adopting a maintenance program of everolimus combined with aromatase inhibitors, outcomes were not improved in patients with metastatic breast cancer who were deemed possible candidates for first-line chemotherapy.
Recognition of the common use of chemotherapy and its potential negative impact on quality of life during the final month of life of patients with metastatic breast cancer is essential to efforts to mitigate this practice.
In a Real-World Setting, the RIBANNA Study Showed Diverse Population Characteristics Among Patients Who Received Ribociclib Treatment
Results of a second interim analysis demonstrate real-world outcomes of treatment with ribociclib, a selective CDK4/6 inhibitor in combination with endocrine therapy.